StockNews.com Initiates Coverage on TherapeuticsMD (NASDAQ:TXMD)

StockNews.com started coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a research note issued on Tuesday. The firm set a “hold” rating on the stock.

TherapeuticsMD Stock Performance

TXMD stock opened at $1.37 on Tuesday. The firm has a 50 day moving average of $1.53 and a 200-day moving average of $1.74. TherapeuticsMD has a 12 month low of $1.15 and a 12 month high of $2.75.

Institutional Investors Weigh In On TherapeuticsMD

A hedge fund recently raised its stake in TherapeuticsMD stock. Clearline Capital LP boosted its holdings in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 636,622 shares of the company’s stock after acquiring an additional 101,282 shares during the quarter. Clearline Capital LP owned 5.52% of TherapeuticsMD worth $1,025,000 at the end of the most recent reporting period. 30.74% of the stock is currently owned by hedge funds and other institutional investors.

About TherapeuticsMD

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.